Balyasny Asset Management
TNXP icon

Balyasny Asset Management’s Tonix Pharmaceuticals TNXP Stock Holding History

Balyasny Asset Management’s Portfolio TNXP Stock Details TNXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.3M Buy
313,082
+127,730
+69% +$1.97M 0.01% 1427
2025
Q4 		$2.9M Buy
+185,352
New +$3.42M ﹤0.01% 1688
2021
Q2 		– Hold
0
– -$45K – 2352
2021
Q1 		– Hold
0
– – – 1688

Other funds holding TNXP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
JHC
Jones Hill Capital New York $466M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Balyasny Asset Management's TNXP Position: Q1 2026 in Review

Balyasny Asset Management increased its Tonix Pharmaceuticals (TNXP) stake by 69% in Q1 2026, buying an estimated $1.97M and bringing the position to 313,082 shares worth $4.3M. The position accounts for 0.01% of the portfolio, ranked #1427.

Balyasny Asset Management first reported a position in TNXP in Q4 2025 and has held it in 2 quarters since. 81 funds tracked by Wall St. Rank hold TNXP as of Q1 2026.

  • Balyasny Asset Management held 313,082 shares of Tonix Pharmaceuticals worth $4.3M as of Q1 2026.
  • Balyasny Asset Management bought 127,730 Tonix Pharmaceuticals shares in Q1 2026, an estimated $1.97M.
  • Tonix Pharmaceuticals made up 0.01% of Balyasny Asset Management's portfolio in Q1 2026, its #1427 holding.
  • Balyasny Asset Management first reported a position in Tonix Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • 81 funds tracked by Wall St. Rank held Tonix Pharmaceuticals as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.